低剂量苏尔福拉和多塞塔克塞尔的组合对前列腺癌细胞系中的线粒体功能和代谢重编程产生影响
Ana Peñata-Taborda1, Pedro Espitia-Pérez1, Lyda Espitia-Pérez1
1Grupo de Investigación Biomédicas y Biología Molecular, Universidad del Sinú E.B.Z., Montería 230001, Colombia.
International journal of molecular sciences
|February 13, 2025
概括
将硫黄 (SFN) 与多塞 (DCT) 结合使用在前列腺癌治疗中显示出有前途. 低剂量SFN:DCT组合疗法有效降低癌细胞活力,并准代谢脆弱性,可能减轻副作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 前列腺癌的单一疗法由于化学抵抗和不良影响而面临局限性.
- 多西 (DCT) 是一种标准化疗剂,但其疗效可能因耐药性和毒性而受到限制.
- 硫甲 (SFN) 是一种天然化合物,已显示出潜在的抗癌特性.
研究的目的:
- 在前列腺癌中研究低剂量硫黄 (SFN) 与多塞 (DCT) 结合的治疗疗效.
- 评估SFN:DCT组合对前列腺癌细胞系中代谢标记物和细胞活性的影响.
- 为了确定组合疗法是否可以在降低剂量的情况下达到与单一疗法相比的疗效.
主要方法:
- 前列腺癌细胞系 (LNCaP和PC-3) 用不同度的SFN和DCT进行治疗.
- 评估了细胞活力,以及包括葡萄糖消耗,乳酸生产,活性氧物种 (ROS),线粒体质量和酶活性在内的代谢标志物.
- SFN:DCT组合被测试在一半降低的IC50值.
主要成果:
- 在LNCaP细胞中,SFN:DCT组合降低了细胞活力,类似于DCT单一治疗 (50%vs. 48%) 和增加了caspase3激活.
- 在PC-3细胞中,SFN:DCT组合诱导了酶3激活,并显著减少了线粒体质量,表明对攻击性表型的有效性.
- 组合疗法在较低剂量下表现出与DCT单一疗法相当的疗效,这表明副作用的潜在减少.
结论:
- 硫福拉和多塞塔克塞尔的组合是早期前列腺癌治疗的有希望的策略.
- 低剂量SFN:DCT疗法保持了治疗效果,同时可能减轻与常规多塞塔克塞尔治疗相关的不良影响.
- 用SFN:DCT针对代谢漏洞提供了一种改善前列腺癌治疗的新方法.
相关概念视频
Electron Transport Chain: Complex I and II
10.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K


